New combo therapy shows promise in kidney cancer fight

NCT ID NCT03203473

Ongoing Disease control Sponsor: Toni Choueiri, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two immunotherapy drugs, nivolumab and ipilimumab, in 85 adults with advanced kidney cancer that could not be removed by surgery. The goal was to see if stopping nivolumab early in those who responded well, or adding ipilimumab in those who did not, could better control the disease. While not a cure, this approach aims to improve long-term management of the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney cancer renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CANCER

Contacts and locations

Show contact details

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02115, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Lifespan Comprehensve Cancer Center

Providence, Rhode Island, 02903, United States
University of California, San Diego Moores Cancer Center

La Jolla, California, 92093, United States
University of Chicago Medical Center

Chicago, Illinois, 60637, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States
University of Utah, Huntsman Cancer Center

Salt Lake City, Utah, 84112, United States
Unviersity of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.